▼ 0.55%
prev close
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Congressional Trades
2
All tracked trades
Members Trading
1
Unique members
Net Activity
+2
2 buys · 0 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-09-22 | BBIOBridgeBio Pharma, Inc. - Common Stock | Buy | $1,001 - $15,000 | 285d ago | — | |
| 2025-08-08 | BBIOBridgeBio Pharma, Inc. - Common Stock | Buy | $1,001 - $15,000 | 313d ago | — |
2025-09-22
Gilbert Cisneros
BBIO
Amount
$1,001 - $15,000
Filed
285d ago
2025-08-08
Gilbert Cisneros
BBIO
Amount
$1,001 - $15,000
Filed
313d ago
Recent News
Powered by Polygon.io
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
Wall Street's Cardiac Bet: Where Diagnostics Meet the Money
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
Trade Timeline
Congressional activity, newest first
Gilbert Cisneros
2025-09-22 · Purchase
$1,001 - $15,000
Gilbert Cisneros
2025-08-08 · Purchase
$1,001 - $15,000